Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium.
Amanda RicciutoKuan LiuWael El-MataryMansi AminAchiya Z AmirMadeleine AumarMarcus AuthMatthew D Di GuglielmoEleonora Druve Tavares FagundesAlexandre Rodrigues FerreiraKatryn N FuruyaNitika GuptaStephen GutherySimon P HorslenKyle JensenBinita M KamathNanda KerkarB G P KootTrevor J LabordaChristine K LeeKathleen M LoomesCara MackMercedes MartinezAldo J Montano-LozaNadia OvchinskyAlexandra PapadopoulouEmily R PeritoPushpa SathyaKathleen B SchwarzUzma ShahEyal ShteyerNisreen SoufiJames Patrick StevensAmy TaylorM Elizabeth TessierPamela ValentinoMarek WoynarowskiMark Deneaunull nullPublished in: Alimentary pharmacology & therapeutics (2024)
Vancomycin was associated with greater odds of IBD clinical and endoscopic remission. Additional, preferably randomised, controlled studies are needed to characterise efficacy using objective markers of mucosal inflammation, and to examine safety and define optimal dosing.